Ypsomed expands the mylife(TM) Diabetescare product range
The new mylife(TM) Roto(TM) infusion set with 360-degree freedom of movement
Simon Michel, Senior Vice President Marketing & Sales, is enthusiastic: "Because of the 360-degree rotational freedom of its infusion tube, the mylife(TM) Roto(TM) infusion set is ideal for an active lifestyle. With mylife(TM) Rotosoft(TM) and mylife(TM) Rotofine(TM) , we are enhancing the mylife(TM) Diabetescare product portfolio from Ypsomed and offering our customers greater freedom in their lives." Another bonus is that mylife(TM) Roto(TM) is so inconspicuous. The tape is semi-transparent, and the set itself has a very low profile with a height of only six millimetres. The set is also easy to attach and user-friendly. Selecting the infusion site is just as simple, and the set can be connected and disconnected easily in any position. A click indicates that everything is correctly fitted into place, providing the patient with the security required. In addition, the mylife(TM) Roto(TM) infusion set is attached using an innovative, heat-activated tape that ensures it is held securely.
mylife(TM) Roto(TM) is now available in Germany in two versions: the mylife(TM) Rotosoft(TM) has a flexible Teflon catheter, which is one of the smallest of its kind on the market and offers maximum comfort during use. The mylife(TM) Rotofine(TM) has a high-quality steel cannula, which is also one of the thinnest and shortest steel cannulas currently available on the market.
You can find more information about mylife(TM) Roto(TM) at www.mylife-diabetescare.com.
The Ypsomed Group is the leading independent developer and manufacturer of injection systems for self-medication and a recognised diabetes specialist with more than 25 years' experience. The Ypsomed Group, which emerged in 2003 from the well-known Disetronic Group, today offers insulin pumps, injection systems and pen needles for diabetes, growth hormone and infertility treatments as well as for other therapeutic fields. Ypsomed is an innovation and technology leader with an extensive patent portfolio and is the preferred partner of pharmaceutical and biotech companies in the self-medication sector. The Ypsomed Group has its headquarters in Burgdorf, Switzerland. It has several manufacturing sites in Switzerland as well as specialist diabetes marketing companies throughout Europe. The Ypsomed Group employs a staff of approximately 1,150.